When Antipsychotics Imitate Epilepsy: Diagnostic Dilemma in a Case of Treatment-Resistant Schizophrenia
Keywords:
Anticholinergics, Antipsychotics, Clozapine, Electroencephalogram, Haloperidol, Lamotrigine, Oculogyric Crisis, Schizophrenia, Seizure DisorderAbstract
Oculogyric crisis (OGC), a form of acute dystonia, is a recognized adverse effect of antipsychotics. However, certain seizure disorders can mimic OGC, complicating diagnosis and treatment. This report describes a rare case of seizure disorder presenting as OGC in a patient with treatment-resistant schizophrenia, highlighting a critical diagnostic challenge in clinical psychiatry. This is a case of a 21-year-old female with a 3-year history of schizophrenia developed recurrent upward eye deviation episodes after switching antipsychotics from Olanzapine to Aripiprazole. These were initially diagnosed as antipsychotic-induced OGC but failed to respond to standard anticholinergic therapy. The introduction of Clozapine improved her psychosis but exacerbated the eye movements and led to new symptoms including jerky limb movements, stammering, and two episodes of loss of consciousness with postictal confusion and tongue biting. Electroencephalogram (EEG) revealed generalized rhythmic slowing, suggestive of an underlying seizure disorder. Her symptoms resolved following cross-tapering of Clozapine to Haloperidol and initiation of
Lamotrigine. This case underscores the importance of considering epilepsy in patients presenting with movement abnormalities unresponsive to anticholinergics, especially in the presence of a seizure history. Clozapine is known to lower the seizure threshold, potentially unmasking latent epilepsy. EEG findings, although non-specific, supported cortical dysfunction. The favorable response to antiepileptic therapy reinforced the revised diagnosis. Clinicians should maintain a high index of suspicion for seizure disorders in schizophrenia patients presenting with atypical or treatment- resistant movement symptoms. Comprehensive neurological assessment and individualized pharmacologic strategies, including EEG and antiepileptic therapy, are essential for accurate diagnosis and effective management.
References
1. Ajnakina O, Stubbs B, Gaughran F, Murray RM, David AS. Antipsychotic-induced acute dystonia: a meta-analysis and review. Eur Psychiatry. 2021;64(1):e59.
2. Cornett EM, Novitch MB, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17(2):162–74.
3. Besag FMC, Ahmed F, Kandler R. Oculogyric crisis misdiagnosed as seizures: a diagnostic pitfall. Seizure. 2020;81:276–8.
4. Chan EW, Lau WCY, Leung WMT, Mok VC, Chen EYH, Wong ICK. Psychotropic drugs and risk of seizures: a self-controlled case series study. PLoS One. 2022;17(3):e0264917.
5. Veerman SR, Schulte PFJ, Smith JD, Luykx JJ. Clozapine-induced seizures: a systematic review and meta-analysis. Lancet Psychiatry. 2023;10(1):20–30.
6. Ekinci O, Akay A, Caykoylu A. Oculogyric crisis associated with aripiprazole in a young adult: case report and literature review. Clin Neuropharmacol. 2016;39(6):297–9.
7. Albayrak Y, Ünal ŞN, Yıldız M, Yüksel T, Beyazyüz M. EEG abnormalities in patients with schizophrenia receiving clozapine: clinical correlates and follow-up. Neuropsychiatr Dis Treat. 2017;13:2083–9.
8. Kaster TS, Daskalakis ZJ, Blumberger DM. Clozapine and electroencephalographic abnormalities: a systematic review. Schizophr Res. 2018;199:63–72.
9. Bilo L, Meo R, Nappi C. Epilepsy and forced normalization: clinical relevance and therapeutic implications. Front Neurol. 2020;11:517256.
10. Santos NCS, Rodrigues J, Martins MJ, Silva DF. EEG slowing and cognitive dysfunction in schizophrenia: a quantitative EEG study. Front Psychiatry. 2022;13:877898.
11. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–82.
12. Erol A, Putgul G, Berkol TD, Mete L. Lamotrigine as adjunct therapy in schizophrenia: a meta-analysis. J Psychopharmacol. 2017;31(4):389–400.
